Sam-A Pharm Q1 earnings slump, but dividend hike & solid finances

Q1 2026 (consolidated) revenue 17.63 bn KRW (down 28% YoY), operating profit 2.08 bn (down 72%), net income 2.23 bn (down 64.5%) due to lower respiratory patient numbers
Paid 5.19 bn in dividends for FY2025 (up from 4.88 bn previous year), approx. 815 won per share (vs. 767 won)
Total borrowings 1.14 bn, cash equivalents 14.67 bn → net cash of 13.53 bn; capital gearing ratio not calculated (net cash position)
3 pending lawsuits as defendant; collateral provided on assets worth 20.2 bn (land & buildings)
R&D expenses 1.71 bn (9.7% of revenue), up from 0.98 bn (4.0%) in prior year period